Review
Cell Biology
Zachary A. Haynes, Abhimanyu Chandel, Christopher S. King
Summary: The article provides a comprehensive review of pulmonary hypertension in interstitial lung disease, including its pathophysiology, updated diagnostic approaches, and recent clinical trials, offering an effective approach for medical management.
Article
Respiratory System
Lucilla Piccari, Stephen John Wort, Federica Meloni, Monica Rizzo, Laura C. Price, Lavinia Martino, Elena Salvaterra, Laura Scelsi, Manuel Lopez Meseguer, Isabel Blanco, Adriana Callari, Virginia Perez Gonzalez, Fabio Tuzzolino, Colm McCabe, Diego Agustin Rodriguez Chiaradia, Patrizio Vitulo
Summary: The impact of borderline pulmonary hypertension (PH) on survival in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) remains unclear. However, in ILD, any level of PH is associated with worse survival, while in COPD, only severe PH leads to poorer outcomes.
Article
Critical Care Medicine
Nicholas A. Kolaitis
Summary: Lung transplantation is a unique and effective treatment option for patients with end-stage pulmonary arterial hypertension. However, these patients face various challenges and inequities in the organ allocation process, resulting in less favorable long-term outcomes.
Article
Cardiac & Cardiovascular Systems
Jacqueline T. T. DesJardin, Yana Svetlichnaya, Nicholas A. A. Kolaitis, Steven R. R. Hays, Jasleen Kukreja, Nelson B. B. Schiller, Lucas S. S. Zier, Jonathan P. P. Singer, Teresa De Marco
Summary: Noninvasive estimation of pulmonary hemodynamics, such as echocardiographic pulmonary artery systolic pressure (ePASP), is commonly used but has limitations in the advanced lung disease population. This study aimed to investigate the use of echocardiographic pulmonary vascular resistance (ePVR) in this population. The ePVR models correlated strongly with invasively determined PVR and showed good accuracy, although with moderate precision. The ePVR models also had similar performance to ePASP in estimating invasive hemodynamics and screening for pulmonary hypertension.
PULMONARY CIRCULATION
(2023)
Article
Oncology
Kuo-Chin Chiu, Wei-Chun Lin, Chia-Lun Chang, Szu-Yuan Wu
Summary: COPD and its severity are significant independent risk factors for all-cause mortality in patients with lung SCC receiving definitive CCRT. Hospitalization for COPDAE within 1 year before CCRT is a significant independent risk factor for lung cancer death in these patients.
Article
Critical Care Medicine
Steven D. Nathan, Chunqin Deng, Christopher S. King, Hilary M. DuBrock, Jean Elwing, Sudarshan Rajagopal, Franz Rischard, Sandeep Sahay, Meredith Broderick, Eric Shen, Peter Smith, Victor F. Tapson, Aaron B. Waxman
Summary: Higher dosages of inhaled treprostinil have been shown to have greater benefits in preventing clinical worsening and achieving clinical improvement in patients with pulmonary hypertension resulting from interstitial lung disease.
Article
Medicine, General & Internal
Rong Jiang, Lan Wang, Qin-Hua Zhao, Cheng Wu, Ping Yuan, Shang Wang, Rui Zhang, Su-Gang Gong, Wen-Hui Wu, Jing He, Hong-Ling Qiu, Ci-Jun Luo, Jin-Ming Liu, Zhi-Cheng Jing
Summary: We established and validated a novel nomogram using echocardiographic parameters to predict all-cause death in patients with severe CLD-PH.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Jawad Salman, Beeke-Alina Bernhard, Fabio Ius, Reza Poyanmehr, Wiebke Sommer, Khalil Aburahma, Hani Alhadidi, Thierry Siemeni, Christian Kuehn, Murat Avsar, Axel Haverich, Gregor Warnecke, Igor Tudorache
Summary: This study aimed to identify risk factors for the need of intra-operative ECMO use in lung transplant patients with pulmonary fibrosis. Factors such as preoperative proof of pulmonary hypertension, mean pulmonary arterial pressure, and pulmonary vascular resistance were identified as risk factors, while increased recipient body surface area and higher cardiac output were protective factors. The post-operative course was found to be more complicated in the ECMO+ group, although long-term survival did not differ significantly among groups.
ANNALS OF THORACIC SURGERY
(2021)
Article
Critical Care Medicine
Carmine Dario Vizza, Marius M. Hoeper, Doerte Huscher, David Pittrow, Nicola Benjamin, Karen M. Olsson, H. Ardeschir Ghofrani, Matthias Held, Hans Klose, Tobias Lange, Stephan Rosenkranz, Daniel Dumitrescu, Roberto Badagliacca, Martin Claussen, Michael Halank, Anton Vonk-Noordegraaf, Dirk Skowasch, Ralf Ewert, J. Simon R. Gibbs, Marion Delcroix, Andris Skride, Gerry Coghlan, Silvia Ulrich, Christian Opitz, Harald Kaemmerer, Oliver Distler, Ekkehard Grunig
Summary: The study investigated the outcomes of patients with pulmonary hypertension in chronic obstructive pulmonary disease (COPD) compared to patients with idiopathic pulmonary arterial hypertension (IPAH). Patients with COPD-related pulmonary hypertension had worse functional status and survival rates compared to IPAH patients. Risk factors for poor outcomes in COPD-related pulmonary hypertension included sex, 6-minute walk distance, and pulmonary vascular resistance.
Article
Cardiac & Cardiovascular Systems
Amadeo-Jose Wals-Rodriguez, Maria-Jose Rodriguez-Puras, Rocio Garcia-Orta, Juan Robledo, Eduardo Moreno, Carmen Federero, Rocio Camacho, Begona Manso, Nuria Hernandez, Jose Maria Cubero, Raquel Ladron Abia, Pilar Cejudo Ramos, Antonio Ordonez, Pastora Gallego
Summary: The study found that the survival rate of adults with PAH-CHD receiving vasodilator treatment was 65%, with the highest mortality rate in the pre-tricuspid group. Older age was associated with higher risk of death, and predictors of poor outcome included pericardial effusion, oxygen saturation, and genetic syndromes.
Review
Critical Care Medicine
Rohit Gupta, Marc A. Judson, Robert P. Baughman
Summary: Advanced sarcoidosis is a form of sarcoidosis that poses a significant risk of organ function loss or death, with the lung being the most commonly affected organ. It can lead to complications such as pulmonary fibrosis and bronchiectasis. Although it affects a small proportion of patients, it is the leading cause of poor outcomes.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2022)
Article
Critical Care Medicine
Athenais Boucly, Laurent Savale, Xavier Jais, Fabrice Bauer, Emmanuel Bergot, Laurent Bertoletti, Antoine Beurnier, Arnaud Bourdin, Helene Bouvaist, Sophie Bulifon, Celine Chabanne, Ari Chaouat, Vincent Cottin, Claire Dauphin, Bruno Degano, Pascal De Groote, Nicolas Favrolt, Yuanchao Feng, Delphine Horeau-Langlard, Mitja Jevnikar, Etienne-Marie Jutant, Zhiying Liang, Pascal Magro, Pierre Mauran, Pamela Moceri, Jean-Francois Mornex, Sylvain Palat, Florence Parent, Francois Picard, Jeremie Pichon, Patrice Poubeau, Gregoire Prevot, Sebastien Renard, Martine Reynaud-Gaubert, Marianne Riou, Pascal Roblot, Olivier Sanchez, Andrei Seferian, Cecile Tromeur, Jason Weatherald, Gerald Simonneau, David Montani, Marc Humbert, Olivier Sitbon
Summary: The study findings suggest that initial triple combination therapy containing parenteral prostacyclin is associated with a higher survival rate in patients with PAH, particularly in younger high-risk patients.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2021)
Article
Medicine, General & Internal
Horst Olschewski
Summary: Chronic lung diseases are strongly linked with pulmonary hypertension, with severe PH possibly originating from COPD as the largest subgroup within COPD and severe PH patients. It is crucial to complete diagnostic procedures and identify the main cause of PH before deciding on PAH drugs.
Article
Critical Care Medicine
Rui-Sheng Wang, Shi Huang, Stephen W. Waldo, Edward Hess, Madhura Gokhale, Shelsey W. Johnson, Katarina Zeder, Gaurav Choudhary, Jane A. Leopold, William M. Oldham, Gabor Kovacs, Matthew S. Freiberg, Ryan J. Tedford, Bradley A. Maron, Evan L. Brittain
Summary: This study aims to identify clinical markers and therapeutic targets that inform survival in patients with pulmonary hypertension (PH). The results suggest that elevated pulmonary arterial compliance (PAC) greater than 3.0 ml/mmHg is associated with improved survival, especially in patients with precapillary PH.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Article
Medicine, General & Internal
Aaron Waxman, Ricardo Restrepo-Jaramillo, Thenappan Thenappan, Ashwin Ravichandran, Peter Engel, Abubakr Bajwa, Roblee Allen, Jeremy Feldman, Rahul Argula, Peter Smith, Kristan Rollins, Chunqin Deng, Leigh Peterson, Heidi Bell, Victor Tapson, Steven D. Nathan
Summary: In patients with pulmonary hypertension due to interstitial lung disease, inhaled treprostinil significantly improved exercise capacity and clinical outcomes compared to placebo in a 16-week trial. Adverse events such as cough, headache, dyspnea, dizziness, nausea, fatigue, and diarrhea were commonly reported.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)